AngioDynamics, Inc. (ANGO - Free Report) recently acquired Eximo Medical Ltd. – an early commercial stage medical device company – and its proprietary 355nm wavelength laser-technology platform. Notably, Eximo’s proprietary laser technology will ably complement AngioDynamics’ existing Vascular Interventions and Therapies (VIT) product portfolio.
For investors’ notice, Eximo’s proprietary laser technology has received 510 (k) clearance with respect to the treatment of Peripheral Artery Disease (PAD). The technology is a significant breakthrough among medical devices used in atherectomy procedures to treat PAD currently. Notably, this technology is the only system that has the ability to deliver short, high-powered pulsed-laser energy in 355nm wavelength without compromising the integrity of its fiber optic cables during atherectomy procedures.
Financial Details of the Acquisition
AngioDynamics made the acquisition with $46 million in up-front consideration, with up to $20 million of contingent consideration related to certain technical and revenue milestones. The transaction is being funded exclusively in cash.
Benefits of the Deal
Eximo’s excellent and foundational technology will enhance AngioDyanamic’s portfolio, which will change the way patients with PAD receive treatment.
Further, the buyout will enable AngioDyanmics to foray into a growing and lucrative market (valued at more than $500 million) with an innovative medical solution providing much more versatility, broad array of treatments and robust clinical data to support its efficiency.
Interestingly, this proprietary technology complements AngioDynamics’ leading thrombus management and venous insufficiency technologies.
Speaking of the expansion of AngioDyanamics’ VIT product portfolio, in the fiscal first-quarter 2020, VIT revenues grossed $28.9 million, up 1.1% from the prior-year quarter’s figure. Per management, strong growth in AngioVac and Thrombolytic product line drove revenues.
Other Acquisitions
AngioDynamics continues to expand presence on the back of acquisitions and strategic alliances. The company recently concluded its acquisition of RadiaDyne, a privately held medical diagnostic and device company with two different product lines. It is expected to aid AngioDynamics radiation portfolio. Notably, the buyouts of BioSentry and RadiaDyne have proven to be accretive for AngioDynamics’ Oncology business in recent times.
Market Prospects
Per a report by Fortune Business Insights, the global medical lasers market size (valued at $3.79 billion) is anticipated to reach $12.33 billion by 2026 at a CAGR of 15.9% from the current year.
The growing need for medical lasers for the treatment of several diseases and rising demand for non-invasive treatments are some of the factors fueling the medical lasers market growth.
Some other key players in the medical instruments space are Abiomed, Inc. , Accuray Incorporated (ARAY - Free Report) and Avanos Medical, Inc. (AVNS - Free Report) .
Abiomed is engaged in developing, manufacturing and marketing of medical products, designed to assist or replace the pumping function of the failing heart. The company’s main product line — Impella — comprises Impella 2.5, Impella 5.0, Impella LD, Impella CP and Impella RP.
Accuray designs, develops, and sells radiosurgery and radiation therapy systems for treatment of tumors in the body. The company’s product suite includes the CyberKnife Systems and the TomoTherapy Systems.
Avanos Medical is a medical technology company that offers infection prevention, surgical, respiratory, digestive health and pain management solutions. The company operates through two segments — Chronic Care and Pain Management.
Wall Street’s Next Amazon
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.
Click for details >>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
AngioDynamics, Inc. (ANGO - Free Report) recently acquired Eximo Medical Ltd. – an early commercial stage medical device company – and its proprietary 355nm wavelength laser-technology platform. Notably, Eximo’s proprietary laser technology will ably complement AngioDynamics’ existing Vascular Interventions and Therapies (VIT) product portfolio.
For investors’ notice, Eximo’s proprietary laser technology has received 510 (k) clearance with respect to the treatment of Peripheral Artery Disease (PAD). The technology is a significant breakthrough among medical devices used in atherectomy procedures to treat PAD currently. Notably, this technology is the only system that has the ability to deliver short, high-powered pulsed-laser energy in 355nm wavelength without compromising the integrity of its fiber optic cables during atherectomy procedures.
Financial Details of the Acquisition
AngioDynamics made the acquisition with $46 million in up-front consideration, with up to $20 million of contingent consideration related to certain technical and revenue milestones. The transaction is being funded exclusively in cash.
Benefits of the Deal
Eximo’s excellent and foundational technology will enhance AngioDyanamic’s portfolio, which will change the way patients with PAD receive treatment.
Further, the buyout will enable AngioDyanmics to foray into a growing and lucrative market (valued at more than $500 million) with an innovative medical solution providing much more versatility, broad array of treatments and robust clinical data to support its efficiency.
Interestingly, this proprietary technology complements AngioDynamics’ leading thrombus management and venous insufficiency technologies.
Speaking of the expansion of AngioDyanamics’ VIT product portfolio, in the fiscal first-quarter 2020, VIT revenues grossed $28.9 million, up 1.1% from the prior-year quarter’s figure. Per management, strong growth in AngioVac and Thrombolytic product line drove revenues.
Other Acquisitions
AngioDynamics continues to expand presence on the back of acquisitions and strategic alliances. The company recently concluded its acquisition of RadiaDyne, a privately held medical diagnostic and device company with two different product lines. It is expected to aid AngioDynamics radiation portfolio. Notably, the buyouts of BioSentry and RadiaDyne have proven to be accretive for AngioDynamics’ Oncology business in recent times.
Market Prospects
Per a report by Fortune Business Insights, the global medical lasers market size (valued at $3.79 billion) is anticipated to reach $12.33 billion by 2026 at a CAGR of 15.9% from the current year.
The growing need for medical lasers for the treatment of several diseases and rising demand for non-invasive treatments are some of the factors fueling the medical lasers market growth.
Some other key players in the medical instruments space are Abiomed, Inc. , Accuray Incorporated (ARAY - Free Report) and Avanos Medical, Inc. (AVNS - Free Report) .
Abiomed is engaged in developing, manufacturing and marketing of medical products, designed to assist or replace the pumping function of the failing heart. The company’s main product line — Impella — comprises Impella 2.5, Impella 5.0, Impella LD, Impella CP and Impella RP.
Accuray designs, develops, and sells radiosurgery and radiation therapy systems for treatment of tumors in the body. The company’s product suite includes the CyberKnife Systems and the TomoTherapy Systems.
Avanos Medical is a medical technology company that offers infection prevention, surgical, respiratory, digestive health and pain management solutions. The company operates through two segments — Chronic Care and Pain Management.
Wall Street’s Next Amazon
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.
Click for details >>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Get the latest research report on ARAY - FREE
Get the latest research report on ANGO - FREE
Get the latest research report on AVNS - FREE